Related Experiment Video
Updated: Jul 28, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy
S K Chan1, W J Gullick, M E Hill
1Cancer Biology Laboratory, Research School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom.
Abstract:
The targeting of the ATP binding pocket of the epidermal growth factor receptor (EGFR) tyrosine kinase, by the small molecule drugs gefitinib and erlotinib, represents a promising new therapeutic strategy in non-small cell lung cancer. However, it is now apparent that only a subset of patients responds to such treatment. Two publications in early 2004 reported the presence of activating mutations in the EGFR tyrosine kinase gene conferring exquisite sensitivity to these drugs. Several publications have since reported prospective data consistent with this finding. This brief review summarises the mutation data from 15 such studies in terms of mutation frequency by clinicopathological features and correlation with response to tyrosine kinase inhibition. A new paradigm for the routine detection of such mutations is needed to facilitate patient selection for treatment and further studies.
Insights
Activating mutations in the epidermal growth factor receptor (EGFR) gene predict response to tyrosine kinase inhibitors in non-small cell lung cancer. Routine mutation detection is crucial for selecting patients for targeted therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- Targeting the epidermal growth factor receptor (EGFR) tyrosine kinase with gefitinib and erlotinib offers a new therapeutic strategy for non-small cell lung cancer (NSCLC).
- However, patient response to these tyrosine kinase inhibitors (TKIs) is variable, indicating the need to identify predictive biomarkers.
Purpose of the Study:
- To review mutation data from 15 studies on EGFR tyrosine kinase gene mutations in NSCLC.
- To analyze mutation frequency in relation to clinicopathological features and response to TKIs.
Main Methods:
- Systematic review of published studies reporting EGFR mutation data.
- Analysis of mutation frequency and correlation with clinical outcomes and TKI response.
Main Results:
- Activating mutations in the EGFR tyrosine kinase gene confer sensitivity to gefitinib and erlotinib.
- Prospective studies confirm the association between EGFR mutations and TKI response in NSCLC patients.
Conclusions:
- EGFR mutation status is a key determinant of response to EGFR-targeted TKIs in NSCLC.
- A new paradigm for routine EGFR mutation detection is required for effective patient selection and personalized treatment strategies.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...